In this article, researched looked at available data to analyze sublingual tacrolimus and provide recommendations for solid organ transplant recipients. Tacrolimus is an anti-rejection (immunosuppressant) medication that is available in many dosage forms but sublingual was analyzed in this study.
Typically, oral tacrolimus is used to prevent organ transplant rejection but due to it’s nature in a clinical setting many different situations occur that may prevent oral delivery. For this reason, the researches wanted to explore the efficacy of a sublingual dosage form. The study found that about 50% of the oral dose needed to be delivered sublingually in order to get the targeted therapeutic effect.
Overall, the study helped to solidify the idea that sublingual dosing could be used as a short-term therapy for patient who cannot receive oral delivery.
Do you think that more drugs should be available sublingually? Especially ones used in a clinical setting?